中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 7
Jul.  2020
Turn off MathJax
Article Contents

Clinical effect of vitamin E in treatment of nonalcoholic fatty liver disease in children: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2020.07.019
Research funding:

 

  • Published Date: 2020-07-20
  • Objective To investigate the clinical effect of vitamin E in the treatment of nonalcoholic fatty liver disease( NAFLD) in children. Methods PubMed,Web of Science,The Cochran Library,Embase,OVID/NEJM,CNKI,and Wanfang Data were searched for the articles on vitamin E in the treatment of NAFLD in children published up to December 2019. The data of 8 parameters were analyzed,i. e.,body mass index( BMI),liver enzymes [alanine aminotransferase( ALT) and aspartate aminotransferase( AST) ],blood lipid levels [triglyceride( TG),total cholesterol( TC),low-density lipoprotein( LDL),and high-density lipoprotein( HDL) ],and remission rate of hepatic steatosis. RevMan 5. 3 was used to perform a Meta-analysis. Continuous variables were analyzed by standardized mean difference( SMD) and 95% confidence interval( CI),and the changes after intervention were analyzed; categorical variables were analyzed by risk difference( RD) and 95% CI. A fixed effects model was used for homogeneous data,and a random effects model was used for heterogeneous data. Funnel plots were used to evaluate publication bias. Results A total of 599 articles were retrieved,among which 9 were included in the Meta-analysis,with 607 subjects in total. Vitamin E significantly improved the level of ALT( SMD =-0. 27,95% CI:-0. 48 to-0. 06,P = 0. 01),but it did not improve the levels of BMI( SMD =-0. 09,95% CI:-0. 28 to 0. 10,P = 0. 34),AST( SMD =-0. 20,95% CI:-0. 42 to 0. 02,P = 0. 07),TG( SMD =-0. 19,95% CI:-0. 51 to 0. 12,P = 0. 22),TCHO( SMD =-0. 11,95% CI:-0. 31 to 0. 08,P = 0. 24),HDL( SMD =-0. 02,95% CI:-0. 27 to 0. 23,P = 0. 88),LDL( SMD =-0. 04,95% CI:-0. 27 to0. 19,P = 0. 72),and the remission rate of hepatic steatosis( RD = 0. 06,95% CI:-0. 05 to 0. 17,P = 0. 29). Conclusion Vitamin E can significantly improve the level of ALT in children with NAFLD and can be considered as an adjuvant drug for clinical treatment.

     

  • loading
  • [1]COBBINA E,AKHLAGHI F.Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J].Drug Metab Rev,2017,49(2):197-211.
    [2]MENCIN AA,LAVINE JE.Nonalcoholic fatty liver disease in children[J].Curr Opin Clin Nutr Metab Care,2011,14(2):151-157.
    [3]BYRNE CD,TARGHER G.NAFLD:A multisystem disease[J].JHepatol,2015,62(1 Suppl):s47-s64.
    [4]RINELLA ME,SANYAL AJ.Management of NAFLD:A stage-based approach[J].Nat Rev Gastroenterol Hepatol,2016,13(4):196-205.
    [5]HARDWICK RN,FISHER CD,CANET MJ,et al.Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease[J].Drug Metab Dispos,2010,38(12):2293-2301.
    [6]PIRGON,BILGIN H,EKMEZ F,et al.Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease[J].J Clin Res Pediatr Endocrinol,2013,5(1):33-39.
    [7]DU J,MA YY,YU CH,et al.Effects of pentoxifylline on nonalcoholic fatty liver disease:A Meta-analysis[J].World J Gastroenterol,2014,20(2):569-577.
    [8]HIGGINS JP,THOMPSON SG,DEEKS JJ,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327(7414):557-560.
    [9]VAJRO P,MANDATO C,FRANZESE A,et al.Vitamin E treatment in pediatric obesity-related liver disease:A randomized study[J].J Pediatr Gastroenterol Nutr,2004,38(1):48-55.
    [10]NOBILI V,MANCO M,DEVITO R,et al.Effect of vitamin E on aminotransferase levels and insulin resistance in children with nonalcoholic fatty liver disease[J].Aliment Pharmacol Ther,2006,24(11-12):1553-1561.
    [11]NOBILI V,MANCO M,DEVITO R,et al.Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease:Arandomized,controlled trial[J].Hepatology,2008,48(1):119-128.
    [12]WANG CL,LIANG L,FU JF,et al.Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children[J].World J Gastroenterol,2008,14(10):1598-1602.
    [13]LAVINE JE,SCHWIMMER JB,van NATTA ML,et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:The TONIC randomized controlled trial[J].JAMA,2011,305(16):1659-1668.
    [14]D'ADAMO E,MARCOVECCHIO ML,GIANNINI C,et al.Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with Vitamin E[J].Free Radic Res,2013,47(3):146-153.
    [15]GHERGHEREHCHI R,HAZHIR N,MOSTAFA GHAREBAGHI M.Lifestyle intervention and vitamin E therapy in obese children with nonalcoholic fatty liver disease[J].J Compr Ped,2013,4(1):62-65.
    [16]MURER SB,AEBERLI I,BRAEGGER CP,et al.Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents[J].J Nutr,2014,144(2):193-201.
    [17]NOBILI V,ALISI A,MOSCA A,et al.The antioxidant effects of hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease,in a clinical trial:A new treatment[J].Antioxid Redox Signal,2019,31(2):127-133.
    [18]HASHIMOTO E,TOKUSHIGE K,LUDWIG J.Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis:Current concepts and remaining challenges[J].Hepatol Res,2015,45(1):20-28.
    [19]TILG H,MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:The multiple parallel hits hypothesis[J].Hepatology,2010,52(5):1836-1846.
    [20]DAY CP.Pathogenesis of steatohepatitis[J].Best Pract Res Clin Gastroenterol,2002,16(5):663-678.
    [21]LEVENE AP,GOLDIN RD.The epidemiology,pathogenesis and histopathology of fatty liver disease[J].Histopathology,2012,61(2):141-152.
    [22]SPAHIS S,DELVIN E,BORYS JM,et al.Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis[J].Antioxid Redox Signal,2017,26(10):519-541.
    [23]HICKMAN I,MACDONALD G.Is vitamin E beneficial in chronic liver disease?[J].Hepatology,2007,46(2):288-290.
    [24]MENG XY,LIU J,WANG L,et al.Effects of ascorbic acid-polyethyleneimine carbon dots on proliferation,apoptosis and oxidative stress of MG63 cells by Golgi stress[J].J Jilin Univ(Med Edit),2019,45(6):1218-1223,1480.(in Chinese)孟许亚,刘杰,王璐,等.抗坏血酸-聚乙烯亚胺复合碳点通过高尔基体应激对MG63细胞增殖、凋亡和氧化应激的影响[J].吉林大学学报(医学版),2019,45(6):1218-1223,1480.
    [25]CHALASANI N,DEEG MA,CRABB DW.Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis[J].Am J Gastroenterol,2004,99(8):1497-1502.
    [26]SEKI S,KITADA T,YAMADA T,et al.In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases[J].J Hepatol,2002,37(1):56-62.
    [27]SARKHY AA,AL-HUSSAINI AA,NOBILI V.Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease?A systematic review and meta-analysis[J].Saudi J Gastroenterol,2014,20(3):143-153.
    [28]SATO K,GOSHO M,YAMAMOTO T,et al.Vitamin E has a beneficial effect on nonalcoholic fatty liver disease:A meta-analysis of randomized controlled trials[J].Nutrition,2015,31(7-8):923-930.
    [29]PHUNG N,PERA N,FARRELL G,et al.Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis[J].Int J Mol Med,2009,24(2):171-180.
    [30]MANCO M,ALISI A,NOBILI V.Risk of severe liver disease in NAFLD with normal ALT levels:A pediatric report[J].Hepatology,2008,48(6):2087-2088.
    [31]WIECKOWSKA A,MCCULLOUGH AJ,FELDSTEIN AE.Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis:Present and future[J].Hepatology,2007,46(2):582-589.
    [32]SAKR HF,ABBAS AM,HAIDARA MA.Swimming,but not vitamin E,ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease[J].J Basic Clin Physiol Pharmacol,2018,29(1):61-71.
    [33]KIM GH,CHUNG JW,LEE JH,et al.Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome:A propensity score-matched cohort study[J].Clin Mol Hepatol,2015,21(4):379-386.
    [34]SANYAL AJ,CHALASANI N,KOWDLEY KV,et al.Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis[J].N Engl JMed,2010,362(18):1675-1685.
    [35]WITTLIN L,LOGOMARSINO JV.Therapeutic effects of vitamin Esupplementation in liver diseases and transplantation[J].J Gastroenterol Hepatol Res,2014,3:1095-1102.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1106) PDF downloads(166) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return